Clifton Life Sciences

Clifton Life Sciences (CLS) is a leader in the emerging field of liquid biopsies. It focuses on the development of blood-based molecular diagnostic tests for personalized oncological medicine. The company’s products and services are based on its proprietary technology involving the identification of molecular signatures for a variety of different cancers. CLS is developing novel molecular genomic blood detection systems for point-of-care diagnostic cancer applications including breast, colon, lung cancer, ovarian, pancreatic, prostate, melanoma, myeloma and neuroendocrine cancers. The CLS platform integrates molecular gene cluster and defines cancer specific signatures. Genomic analysis produces high performance quantitative laboratory test results from venous or fingerprick blood samples.